Ibrutinib Effective for Severe Hairy Cell Leukemia : vimarsa

Ibrutinib Effective for Severe Hairy Cell Leukemia


Ibrutinib Effective for Severe Hairy Cell Leukemia
by Angela Mohan on 
July 22, 2021 at 8:36 AM
Blood.
Hairy cell leukemia has generally a good prognosis for the majority of people affected. But, a small group of patients with variants of the disease do not respond well to existing U.S. Food and Drug Administration (FDA) approved therapies or cannot tolerate the side effects of established therapies.
"There is a critical unmet need for therapy options in this subset of patients to achieve long-term cancer control," said Dr. Kerry Rogers, principal investigator of the clinical trial and a hematologist/scientist at the OSUCCC - James.

Related Keywords

Columbus , Ohio , United States , Kerry Rogers , Lisa Ray , Drug Administration , Ohio State College Of Medicine , Ohio State , Deepa Mehta , கொலம்பஸ் , ஓஹியோ , ஒன்றுபட்டது மாநிலங்களில் , கெர்ரி ரோஜர்ஸ் , லிசா ராய் , ஓஹியோ நிலை கல்லூரி ஆஃப் மருந்து , ஓஹியோ நிலை , தீபா மேத்தா ,

© 2025 Vimarsana